Delcath Q2 Revenue $29.1M, Net Income $2.7M; Initiates New Trials

Delcath Systems reported Q2 2026 product revenue of $29.1 million, a 20.6% increase year-over-year, with net income of $2.7 million. For the first half of 2026, revenue grew to $54.1 million, up 23.2% YoY, but net income decreased significantly to $1.6 million, primarily due to increased R&D and SG&A expenses. The company announced positive results from the CHOPIN clinical trial and initiated Phase 2 trials for HEPZATO in metastatic colorectal cancer and metastatic breast cancer. Delcath maintains a strong liquidity position with $47.5 million in cash and cash equivalents.